Cytokinetics | BiotechTV

top of page

Search

SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more

Jan 16

SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more

He highlights the company's current clinical programs, and talks about how thy are leveraging for the future the unique expertise in...

Cytokinetics’ CEO Robert Blum discusses today’s SEQUOIA-HCM P3 result

Dec 27, 2023

Cytokinetics’ CEO Robert Blum discusses today’s SEQUOIA-HCM P3 result

Robert Blum describes Aficamten’s topline safety, efficacy, and how the company views its competitive profile.

Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December

Nov 20, 2023

Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December

President and CEO Robert Blum describes aficamten's mechanism, the trial's study design, and reflects on Cytokinetics' 25 years.

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Saville's Life Sciences Overview

bottom of page